Articles for tag: adhd, care, drug-interaction, duties, get-sued, GMC, imprisonment, methylphenidate, MHRA, negligence, off-label, off-licence, prescribing, prison, prisoners, schizophrenia, SmPC, standards, treatment

Why Most Psychiatrists are Paddling Blind with Methylphenidate in Contraindication Creek

The issue begins with the Summary of Product Characteristics (SmPC). That’s just the manufacturers raw data and licence specifications that few doctors ever read. For methylphenidate (MPD), the list of contraindications is extensive and spans multiple physiological systems. In the UK regulatory framework, this creates a “red line” established by the MHRA through the drug’s Marketing Authorisation. This article should be informative for psychiatrists, medical line managers and non-medical managers. While clinicians often treat “off-label” prescribing as a routine occurrence, ...

Sitting in the lap of Big Pharma

Following a recent BBC documentary on antidepressants(2023), I was set on a path of deeper inquiry about psychotropic medications and the relationship of Big Pharma to psychiatrists as a group. Then my colleague S.D. got me reading: The Empire of Pain: The Secret History of the Sackler Dynasty. I was driven to do some digging about Big Pharma’s ‘offences’ in general and then sieved the list down to psychotropic medications. Note our disclaimers. This information is gathered from the public ...

Off-label and off-licence prescribing

In the UK, the terms “off-label” and “off-licence” prescribing are often used interchangeably, but they refer to slightly different concepts. The General Medical Council wisely unified both concepts to the term ‘unlicenced prescribing’ . It does not mean ‘illegal prescribing’. Most unlicenced prescribing in the practice of medicine happens in psychiatry. Why is unlicenced prescribing a big deal? In a nutshell, it is because when a medication is used outside of it tested development parameters special precautions ought to be ...